Kasowitz Represents Triad Life Sciences in its Acquisition by ConvaTec Group

Kasowitz Benson Torres is representing medical device company Triad Life Sciences in its acquisition by ConvaTec Group, a global medical solutions company.  Under the merger agreement, which is subject to Hart-Scott-Rodino approval, ConvaTec will pay $125 million at closing, followed by two payments of $25 million each if certain short-term milestones are reached, and additional potential payments of up to $275 million if certain financial performance targets are met within the first two years.

The Kasowitz team representing Triad Life Sciences is led by partner Barry Rutcofsky.